What question did this study set out to answer?

This critical perspective evaluates the role of blood-based biomarkers in Alzheimer's disease diagnosis, focusing on p-tau217 as a leading candidate.

Can the integration of blood-based biomarkers into Alzheimer’s disease diagnosis revolutionize the field?

View Full Paper

Ask AI

Bookmark

Authors

Critical perspective examines the role of blood biomarkers in diagnosing Alzheimer’s disease, suggesting transformative potential.

This critical perspective evaluates the role of blood-based biomarkers in Alzheimer's disease diagnosis, focusing on p-tau217 as a leading candidate.
Critical appraisal of current evidence on plasma phosphorylated tau at threonine 217 (p-tau217) as a blood-based biomarker for AD.
Discussion of the biomarker's analytical performance, diagnostic accuracy, and correlation with CSF and PET biomarkers.
Examination of factors influencing interpretation and potential for clinical integration.
Plasma p-tau217 shows promise as a leading blood-based biomarker for Alzheimer's disease diagnosis.
A stepwise diagnostic approach is recommended, utilizing blood biomarkers as initial tests followed by confirmatory CSF or PET imaging.
Future implications suggest that brain-derived tau biomarkers could replace CSF, enhancing diagnostic efficiency.

Gaetani et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark